Legend Biotech (LEGN) Receivables - Net (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Receivables - Net data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Receivables - Net rose 360.7% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 360.7% YoY) and the FY2025 annual result came in at $13.1 million, up 104.69% from the prior year.
• Receivables - Net eased to $1.7 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $100.0 million in Q4 2023 to a low of $20000.0 in Q3 2023.
• A 5-year average of $15.5 million and a median of $3.3 million in 2024 frame the typical range for Receivables - Net.
• The widest YoY moves for Receivables - Net: up 111056.67% in 2023, down 99.89% in 2023.
• Tracing LEGN's Receivables - Net over 5 years: stood at $90000.0 in 2022, then surged by 111056.67% to $100.0 million in 2023, then plunged by 93.6% to $6.4 million in 2024, then soared by 104.69% to $13.1 million in 2025, then slumped by 87.02% to $1.7 million in 2026.
• The last three Receivables - Net figures came in at $1.7 million (Q1 2026), $13.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.